Abstracts tagged "Cardiovascular disease"

Abstract Number: 2459 • 2014 ACR/ARHP Annual Meeting
Osteoprotegerin CGA Haplotype Protection Against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis
Fernanda Genre¹, Raquel López-Mejías¹, Mercedes García-Bermúdez², Santos Castañeda³, Carlos González-Juanatey⁴, Javier Llorca⁵, Alfonso Corrales¹, Begoña Ubilla¹, Jose A. Miranda-Filloy⁶, Encarnación Amigo⁶, Trinitario Pina Murcia¹, Carmen Gómez-Vaquero⁷, Luis Rodriguez-Rodriguez⁸, Benjamin Fernández Gutierrez⁸, Alejandro Balsa⁹, Dora Pascual-Salcedo⁹, Francisco Javier López-Longo¹⁰, Patricia Carreira¹¹, Ricardo Blanco¹², Isidoro González-Alvaro¹³, Javier Martin¹⁴ and Miguel A González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁴Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁷Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁸Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ⁹Hospital Universitario La Paz, Department of Rheumatology, Madrid, Spain, ¹⁰Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, ¹¹Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, ¹²Hospital Marques de Valdecilla, Santander, Spain, ¹³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁴Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: Rheumatoid arthritis is an inflammatory disease with a high incidence of cardiovascular disease due to accelerated atherosclerosis. Osteoprotegerin (OPG) has been associated with an…
Abstract Number: 1852 • 2014 ACR/ARHP Annual Meeting
Increased Cardiovascular Risk in Patients Recently Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort Study
Katelynn Wilton¹, Floranne C. Ernste², Cynthia S. Crowson³, Eric L. Matteson⁴, Hilal Maradit Kremers⁵ and Marta Sánchez-Menéndez⁶, ¹Medical Scientist Training Program, Mayo Clinic Rochester, Rochester, MN, ²Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Centro Medico de Asturias, Oviedo, Spain
Background/Purpose: Patients diagnosed with rheumatoid arthritis and psoriatic arthritis (PsA) have an increased risk of multiple comorbidities that predispose them to cardiovascular disease (CVD). Although…
Abstract Number: 1376 • 2014 ACR/ARHP Annual Meeting
Angiographic Pattern Among Rheumatoid Arthritis Patients Who Are Hospitalized Due to Acute Coronary Syndrome
Marie Holmqvist¹, Ängla Mantel², Tomas Jernberg³, Stefan James⁴, Solveig Wållberg-Jonsson⁵ and Johan Askling⁶, ¹Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden, ³Department of medicine, Section of Cardiology, Karolinska University Hospital, Stockholm, Sweden, ⁴3Department of Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden, ⁵Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁶Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: We aimed at investigating and to compare the angiographic pattern of stenoses in patients with rheumatoid arthritis (RA) and general population comparators hospitalized due…
Abstract Number: 829 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Deposit of Monosodium Urate Crystals Associates to a More Severe Coronary Calcification in Hyperuricemic Patients with Acute Coronary Syndrome
Mariano Andrés¹, María Amparo Quintanilla², Francisca Sivera¹, Paloma Vela^3,4 and Juan Miguel Ruiz-Nodar⁵, ¹Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ²Sección de Cardiología, Hospital General Universitario de Elda, Alicante, Spain, ³Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ⁴Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ⁵Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, Spain
Background/Purpose: Increased cardiovascular (CV) risk in gout relates to crystal-driven inflammation. Monosodium urate (MSU) crystals are found in ~25% of patients with asymptomatic hyperuricemia (AH)…
Abstract Number: 176 • 2014 ACR/ARHP Annual Meeting
Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both
Svetlana Krasnokutsky¹, Robert T. Keenan², Laura Schneck¹, Craig Tenner³, Helene Strauss⁴, Daria Crittenden⁵, Aaron Lehmann¹ and Michael H. Pillinger¹, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²Rheumatology, Duke University, Durham, NC, ³Medicine, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Amgen, Thousand Oaks, CA
Background/Purpose: Gout is associated with increased CV risk, both dependent on, and independent of traditional CV risk factors. Recent studies suggest that OA, traditionally considered non-inflammatory,…
Abstract Number: 2461 • 2014 ACR/ARHP Annual Meeting
Osteprotegerin Concentrations Are Independently Related to Established Cardiovascular Disease in Rheumatoid Arthritis
Raquel López-Mejías¹, Begoña Ubilla¹, Fernanda Genre¹, Alfonso Corrales¹, José L Hernandez², Ivan Ferraz-Amaro³, Linda Tsang⁴, Javier Llorca⁵, Ricardo Blanco⁶, Carlos González-Juanatey⁷, MA González-Gay^1,4 and Patrick H Dessein⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Department of Internal Medicine, Hospital Universitario Marques de Valdecilla, University of Cantabria, RETICEF, IDIVAL, Santander, Spain, ³Rheumatology, Servicio de Reumatologia. Hospital Universitario de Canarias, Tenerife, Spain, ⁴Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain
Background/Purpose: We determined whether osteoprotegerin (OPG) concentrations are associated with established cardiovascular disease (CVD) amongst patients with rheumatoid arthritis (RA). Methods: OPG concentrations were measured…
Abstract Number: 1865 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study
Neda Amiri¹, Natasha Dehghan², Eric C. Sayre³, Kamran Shojania¹ and J. Antonio Avina-Zubieta⁴, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose Limited literature is available on the incidence of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Granulomatosis with Polyangiitis (GPA). We assessed…
Abstract Number: 1363 • 2014 ACR/ARHP Annual Meeting
Psychosocial Comorbidities Are Independently Associated with Subclinical Atherosclerosis in Rheumatoid Arthritis
Ying Liu¹, Moyses Szklo², Karina Davidson³, Joan Bathon⁴ and Jon Giles³, ¹Internal Medicine, Columbia University Medical Center, New York, NY, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Columbia University Medical Center, New York, NY, ⁴Medicine, Columbia University, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with higher rates of cardiovascular disease (CVD) and subclinical atherosclerosis as well as psychosocial comorbidities, which themselves are associated…
Abstract Number: 838 • 2014 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare?
Elena Myasoedova¹, Arun K. Chandran², Birkan İlhan³, Brittny T. Major⁴, C. John Michet III², Eric L. Matteson² and Cynthia S. Crowson⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Longitudinal studies assessing the effect of changes of RA activity on…
Abstract Number: 156 • 2014 ACR/ARHP Annual Meeting
Colchicine and the Risk of Acute Cardiovascular (CV) Events Among Gout Patients: The New York Department of Veterans Affairs Retrospective Cohort Study
Daria B. Crittenden^1,2, Jessica N. Kimmel^1,2, Virginia C. Pike^1,2, Rebecca Boas^1,2, Daniel Diaz^1,2, Cilian J. White^1,2, Michael DeBerardine^1,2, Grace Kim^1,2, Pajazit Morina^1,2, Avni Shah^1,2, Binita Shah^2,3, Steven P. Sedlis^2,3, Jeffrey D. Greenberg^2,4, Craig T. Tenner^2,5, Christopher J. Swearingen^1,6, Svetlana Krasnokutsky Samuels^1,2, Bruce N. Cronstein¹ and Michael H. Pillinger^1,2, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²VA New York Harbor Health Care System, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Department of Medicine, New York, NY, ⁶Department of Pediatrics and Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
Background/Purpose: Gout patients are at increased risk for CV disease, possibly owing to chronic inflammation. Colchicine is commonly used in gout, and inhibits inflammatory cell…
Abstract Number: 2445 • 2014 ACR/ARHP Annual Meeting
A Distinct Profile of Circulating Microparticles Is Associated with Disease Features in Rheumatoid Arthritis Patients and Impairs Endothelial Functionality in Vitro
Javier Rodríguez-Carrio¹, Mercedes Alperi-López², Patricia López¹, Sara Alonso-Castro², Santiago Rubén Carro-Esteban¹, Javier Ballina-García² and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose Cell-derived microparticles (MPs) could be considered biomarkers of cell damage and activation and they are thought to have a role in cardiovascular (CV) and inflammatory…
Abstract Number: 1846 • 2014 ACR/ARHP Annual Meeting
The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients
Michael Shapiro¹ and Yair Levy², ¹Haim Lebanon 55, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Internal Medicine E, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Accelerated atherosclerosis and cardiovascular disease are the main causes of mortality in Rheumatoid Arthritis (RA). The anti-malarial drug Hydroxychloroquine (HCQ) has long been used…
Abstract Number: 1362 • 2014 ACR/ARHP Annual Meeting
Impact of Rapid Attainment of Stringent Measures of Efficacy in Rheumatoid Arthritis on Patient-Reported Outcomes
EA Alemao¹, S Joo², S Banerjee¹, P Emery³ and M Weinblatt⁴, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Hopewell, NJ, ³University of Leeds, Leeds, United Kingdom, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Treatment guidelines in RA recommend that therapies aim to reach a target of remission or low disease activity (LDA) and that these targets should…
Abstract Number: 836 • 2014 ACR/ARHP Annual Meeting
Categorical Change in 6MWD in Patients with Connective Tissue Disease Associated Pulmonary Arterial Hypertension Receiving Ambrisentan over 3-Years
Aryeh Fischer¹, Virginia D. Steen², Steven Nathan³, Hunter Gillies⁴, James Tislow⁵ and Chris Blair⁶, ¹Rheumatology / ILD Program, National Jewish Health, Denver, CO, ²Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ³Heart Failure/Transplant, Inova Medical Group, Falls Church, VA, ⁴Clinical Research - Cardiovascular, Gilead Sciences, Inc., Foster City, CA, ⁵Medical Affairs, Gilead Sciences, Inc., Foster City, CA, ⁶Biostatistics, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: The 6MWD is a valuable tool for evaluating response to therapy in patients with pulmonary arterial hypertension and may be considered a surrogate measure…
Abstract Number: 154 • 2014 ACR/ARHP Annual Meeting
Cimt in Individuals with Rheumatoid Arthritis Compared to Individuals with Type2 Diabetes
Helen Pahau Sr.^1,2, Leanne Short³, Brian Haluskas⁴, Vibeke Videm⁵ and Ranjeny Thomas⁶, ¹Diamantina Institute, The University of Queensland, Woolloongabba, Australia, ²Diamantina Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ³Cardiovascular Imaging Research Centre, University of Queensland, Woolloongabba, Australia, ⁴Cardiovascular Imaging Research Centre, the University of Queensland, Woolloongabba, Australia, ⁵Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, Trondheim University Hospital,, Trondheim, Norway, ⁶University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose It is well known that patients with RA or Type 2 diabetes (T2DM) have increased risk of atherosclerosis and CVD. Carotid ultrasound measurement of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].